We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.
Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.
Penny Stock of the Day: Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
Today’s penny stock pick is the biotech company, Vistagen Therapeutics, Inc. (NASDAQ: VTGN).
Vistagen Therapeutics, Inc. engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder.
It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
In addition, the company’s clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Website: https://www.vistagen.com/
Latest 10-K report: https://www.vistagen.com/static-files/e513ca8c-3795-4038-8d4e-0dc0c4a05438
Analyst Consensus: As per TipRanks Analytics, based on 4 Wall Street analysts offering 12-month price targets for VTGN in the last 3 months, the stock has an average price target of $14.33, which is nearly 238% upside from current levels.
Analysts | Source: TipRanks.com
Potential Catalysts / Reasons for the Hype:
- The company’s lead candidate fasedienol completed the randomized portion of PALISADE-3 Phase 3 trial for acute SAD treatment; open-label extension is ongoing. This builds on a diverse pipeline of five clinical-stage intranasal pherines.
- The company received institutional backing. Janus Henderson acquired a 13.6% stake in September 2025, signaling confidence.
- There is a significant and growing focus on the development of localized, non-systemic treatments for central nervous system (CNS) disorders and non-systemic treatments.
On analyzing the company’s stock charts, there seem to be multiple bullish indications…
Bullish Indications
#1 Uptrend Channel: The daily chart shows that the stock has been forming an uptrend channel, which is shown as purple color lines. The stock looks poised for a breakout from the trend channel which is a possible bullish indication.
VTGN – Daily Chart
#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.
#3 Price above MAs: The stock is currently above its 50-day as well as 200-day SMA, indicating that the bulls have currently gained control.
#4 Bullish Stoch: The %K line of the stochastic is above the %D line, and has also moved higher from oversold levels, indicating possible bullishness.
#5 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink color dotted line. This looks like a good area for the stock to move higher. The stock is also trading above its 50-week SMA, indicating that the bulls are gaining control.
VTGN – Weekly Chart
#6 Bullish Aroon: The value of Aroon Up (orange line) is above 70 while Aroon Down (blue line) is below 30. This indicates bullishness.
#7 MACD above Signal Line: In the weekly chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.
Recommended Trade (based on the charts)
Buy Levels: If you want to get in on this trade, the ideal buy level for VTGN is above the price of $4.50.
Target Prices: Our first target is $5.60. If it closes above that level, the second target price is $6.40.
Stop Loss: To limit risk, place a stop loss at $3.90. Note that the stop loss is on a closing basis.
Our target potential upside is 43% to 90%.
For a risk of $0.60, our first target reward is $1.10, and the second target reward is $1.90. This is a nearly 1:2 and 1:3 risk-reward trade.
In other words, this trade offers 2x to 3x more potential upside than downside.
Potential Risks / Red Flags:
- The company has a history of net losses.
VTGN – Consolidated Statements of Operations
- Any negative topline data could cause a decline in stock price. PALISADE-3 is a “second shot on goal” after prior trials. Vistagen’s PALISADE-2 Phase 3 trial was successful, meeting its primary and secondary endpoints. However, any negative topline data for PALISADE-3 could cause significant headwinds.
- There is a broader biotech sector volatility.
- The company has ongoing legal proceedings. On February 13, 2025, John Cesario and David Preka filed a civil action, pro in the United States District Court for the Northern District of California (Case No. 4:25-cv-01510) (the Complaint) against the Company.
- Despite being a loss-making company, the executives are being paid significant compensation.
VTGN – Executive Compensation
- The company is a clinical-stage biopharmaceutical company with no approved products or revenues from product sales, and limited experience developing and commercializing new product candidates, which makes it difficult to assess its future viability.
- The company operates in highly competitive and rapidly changing industries and face significant competition.
As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!
Happy Trading!
Trades of the Day Research Team
READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.
Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.
The Guy Who Beat Buffett Shocks the World Again… [sponsor]The New York Times called him "an icon among growth stock investors." The Wall Street Journal said "Most money managers can only dream of having the same success" he's had. His investment fund produced a 4,000% return over a 15-year span, outperforming even the great Warren Buffett. His name is Louis Navellier. And he's just issued an astonishing financial prediction. Click here to see it.